Menu
Search
|

Menu

Close
X

Audentes Therapeutics Inc BOLD.OQ (NASDAQ Stock Exchange Global Market)

33.51 USD
-0.78 (-2.27%)
As of Feb 17
chart
Previous Close 34.29
Open 34.11
Volume 50,847
3m Avg Volume 111,538
Today’s High 34.11
Today’s Low 33.32
52 Week High 41.80
52 Week Low 14.00
Shares Outstanding (mil) 27.78
Market Capitalization (mil) 722.67
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.80 Mean rating from 10 analysts

KEY STATS

Revenue (mm, USD)
FY17
0
FY16
0
FY15
0
EPS (USD)
FY17
-2.581
FY16
-3.009
FY15
-1.259
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
--
5.77
Price to Book (MRQ)
vs sector
4.46
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
2.48
16.52
LT Debt to Equity (MRQ)
vs sector
2.39
12.22
Return on Investment (TTM)
vs sector
-57.99
14.43
Return on Equity (TTM)
vs sector
-145.70
16.13

EXECUTIVE LEADERSHIP

Matthew Patterson
President, Chief Executive Officer, Co-Founder, Director, Since
Salary: $441,760.00
Bonus: --
Thomas Schuetz
Co-Founder, Independent Director, Since 2013
Salary: --
Bonus: --
Thomas Soloway
Chief Financial Officer, Senior Vice President, Since 2017
Salary: $360,500.00
Bonus: --
Natalie Holles
Chief Operating Officer, Senior Vice President, Since 2015
Salary: $360,500.00
Bonus: --
David Nagler
Senior Vice President - Human Resources and Corporate Affairs, Since 2015
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

600 California St Fl 17
SAN FRANCISCO   CA   94108-2725

Phone: +1415.6386556

Audentes Therapeutics, Inc. is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT). The Company's subsidiary is Audentes Therapeutics UK Ltd. As of September 30, 2016, the Company had not generated any revenues.

SPONSORED STORIES